Terms: = Ovarian cancer AND ITK, PSCTK2, 3702, Q08881, ENSG00000113263, EMT, MGC126258, LYK, MGC126257 AND Treatment
323 results:
1. Tumour-derived exosome SNHG17 induced by oestrogen contributes to ovarian cancer progression via the CCL13-CCR2-M2 macrophage axis.
Liang H; Geng S; Wang Y; Fang Q; Xin Y; Li Y
J Cell Mol Med; 2024 May; 28(9):e18315. PubMed ID: 38680032
[TBL] [Abstract] [Full Text] [Related]
2. ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC.
Böpple K; Oren Y; Henry WS; Dong M; Weller S; Thiel J; Kleih M; Gaißler A; Zipperer D; Kopp HG; Aylon Y; Oren M; Essmann F; Liang C; Aulitzky WE
Cell Death Dis; 2024 Apr; 15(4):290. PubMed ID: 38658567
[TBL] [Abstract] [Full Text] [Related]
3. Functional analysis and validation of oncodrive gene AP3S1 in ovarian cancer through filtering of mutation data from whole-exome sequencing.
Kong D; Wu Y; Liu Q; Huang C; Wang T; Huang Z; Gao Y; Li Y; Guo H
Eur J Med Res; 2024 Apr; 29(1):231. PubMed ID: 38609993
[TBL] [Abstract] [Full Text] [Related]
4. FSH induces emt in ovarian cancer via ALKBH5-regulated Snail m6A demethylation.
Xu X; Zhuang X; Yu H; Li P; Li X; Lin H; Teoh JP; Chen Y; Yang Y; Cheng Y; Chen W; Fu X
Theranostics; 2024; 14(5):2151-2166. PubMed ID: 38505602
[No Abstract] [Full Text] [Related]
5. cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter.
Feng S; Ding B; Dai Z; Yin H; Ding Y; Liu S; Zhang K; Lin H; Xiao Z; Shen Y
J Transl Med; 2024 Mar; 22(1):280. PubMed ID: 38491511
[TBL] [Abstract] [Full Text] [Related]
6. Unraveling the molecular mechanisms of lymph node metastasis in ovarian cancer: focus on MEOX1.
Li J; Sun Y; Zhi X; Sun Y; Abudousalamu Z; Lin Q; Li B; Yao L; Chen M
J Ovarian Res; 2024 Mar; 17(1):61. PubMed ID: 38486335
[TBL] [Abstract] [Full Text] [Related]
7. Tabersonine Enhances Olaparib Sensitivity through FHL1-Mediated Epithelial-Mesenchymal Transition in an ovarian Tumor.
Chen X; Yan Y; Liu Y; Yi Q; Xu Z
J Nat Prod; 2024 Apr; 87(4):837-848. PubMed ID: 38417401
[TBL] [Abstract] [Full Text] [Related]
8. The miR-1290/OGN axis in ovarian cancer-associated fibroblasts modulates cancer cell proliferation and invasion.
Jiang B; Xiao S; Zhang S; Xiao F
J Ovarian Res; 2024 Feb; 17(1):52. PubMed ID: 38402185
[TBL] [Abstract] [Full Text] [Related]
9. Deciphering the oncogenic landscape: Unveiling the molecular machinery and clinical significance of LncRNA TMPO-AS1 in human cancers.
Saraswat SK; Mahmood BS; Ajila F; Kareem DS; Alwan M; Athab ZH; Shaier JB; Hosseinifard SR
Pathol Res Pract; 2024 Mar; 255():155190. PubMed ID: 38330619
[TBL] [Abstract] [Full Text] [Related]
10. Signatures of tumor-associated macrophages correlate with treatment response in ovarian cancer patients.
Gao Y; Qi Y; Shen Y; Zhang Y; Wang D; Su M; Liu X; Wang A; Zhang W; He C; Yang J; Dai M; Wang H; Cai H
Aging (Albany NY); 2024 Jan; 16(1):207-225. PubMed ID: 38175687
[TBL] [Abstract] [Full Text] [Related]
11. Bone morphogenetic protein-9 downregulates StAR expression by inducing snail expression via SMAD1/5/8 signaling in human granulosa-lutein cells.
Liu B; Fu B; Zhou S; Wang H; Bi B; Guo M; Cheng JC; Fang L
Mol Cell Endocrinol; 2024 Mar; 582():112126. PubMed ID: 38109991
[TBL] [Abstract] [Full Text] [Related]
12. Curcumin modulates cell type-specific miRNA networks to induce cytotoxicity in ovarian cancer cells.
Ravindran F; Mhatre A; Koroth J; Narayan S; Choudhary B
Life Sci; 2023 Dec; 334():122224. PubMed ID: 38084671
[TBL] [Abstract] [Full Text] [Related]
13. Promising applications of nanotechnology in inhibiting chemo-resistance in solid tumors by targeting epithelial-mesenchymal transition (emt).
Tangsiri M; Hheidari A; Liaghat M; Razlansari M; Ebrahimi N; Akbari A; Varnosfaderani SMN; Maleki-Sheikhabadi F; Norouzi A; Bakhtiyari M; Zalpoor H; Nabi-Afjadi M; Rahdar A
Biomed Pharmacother; 2024 Jan; 170():115973. PubMed ID: 38064969
[TBL] [Abstract] [Full Text] [Related]
14. RUNX1 knockdown induced apoptosis and impaired emt in high-grade serous ovarian cancer cells.
Chen Y; He Z; Yang S; Chen C; Xiong W; He Y; Liu S
J Transl Med; 2023 Dec; 21(1):886. PubMed ID: 38057816
[TBL] [Abstract] [Full Text] [Related]
15. Comparative analysis of syngeneic mouse models of high-grade serous ovarian cancer.
Cook DP; Galpin KJC; Rodriguez GM; Shakfa N; Wilson-Sanchez J; Echaibi M; Pereira M; Matuszewska K; Haagsma J; Murshed H; Cudmore AO; MacDonald E; Tone A; Shepherd TG; Petrik JJ; Koti M; Vanderhyden BC
Commun Biol; 2023 Nov; 6(1):1152. PubMed ID: 37957414
[TBL] [Abstract] [Full Text] [Related]
16. ARID5B promoted the histone demethylation of SORBS2 and hampered the metastasis of ovarian cancer.
Deng Y; Dong Y; Wu L; Zhang Q; Yang L
Pathol Res Pract; 2023 Dec; 252():154911. PubMed ID: 37948999
[TBL] [Abstract] [Full Text] [Related]
17. cancer stemness kinase inhibitor amcasertib: a promising therapeutic agent in ovarian cancer stem and cancer cell models with different genetic profiles.
Guler Kara H; Ozates NP; Asik A; Gunduz C
Med Oncol; 2023 Oct; 40(12):342. PubMed ID: 37891391
[TBL] [Abstract] [Full Text] [Related]
18. Snail transcription factors as key regulators of chemoresistance, stemness and metastasis of ovarian cancer cells.
Kielbik M; Przygodzka P; Szulc-Kielbik I; Klink M
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):189003. PubMed ID: 37863122
[TBL] [Abstract] [Full Text] [Related]
19. Effect of alpha lipoic acid on epithelial mesenchymal transition in SKOV-3 cells.
Önder E; Çil N; Seçme M; Mete GA
Gene; 2024 Jan; 892():147880. PubMed ID: 37813206
[TBL] [Abstract] [Full Text] [Related]
20. Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas.
Machino H; Dozen A; Konaka M; Komatsu M; Nakamura K; Ikawa N; Shozu K; Asada K; Kaneko S; Yoshida H; Kato T; Nakayama K; Saloura V; Kyo S; Hamamoto R
Exp Mol Med; 2023 Oct; 55(10):2205-2219. PubMed ID: 37779141
[TBL] [Abstract] [Full Text] [Related]
[Next]
